Welcome, Guest. Please login or register.
May 20, 2024, 06:38:59 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 192
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 172
Total: 172


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: I am waiting for Vosevi, a few questions  (Read 5791 times)

0 Members and 1 Guest are viewing this topic.

Offline mcmaklin

  • Member
  • Posts: 52
I am waiting for Vosevi, a few questions
« on: May 20, 2018, 10:02:28 am »
I have relapsed after Viekira and Exviera in November 2015, genotype 1b.

Now I am waiting for Vosevi which I hope to get in October. I am still thinking if I should not take Ribavirin additionally. I do not want to take it.

1. How many people from the forum where taking Vosevi for genotype 1b? Do you know anyone, any real-time data? If you know anyone on the forum please let me know.
2. I am trying to explain WHY Viekira+Exviera did not work for the L31M. Is it supposed not to work for this well? 

From my findings:
NS-3 condones covered 1-181
NS3 region (w.r.t M58335) - S7A, V48I, A66G, P86Q, K87A, P89S, F147L, V170l
Ns3 region (w.r.t H77) - I35V, T42S,T61S, R62K, I64L, S66G, V71I,I72T, P86Q, Q89S, , S91A, I132V, A147L, L153I, N174S, L175M
Resistance Analysis
Drug     Predicition Scored mutations
Asunaprevir suspecitble none
Boceprevir susbstituion on second position.      170I
Grazoprevir suspectible none
Paritaprevir suspectible none
Simeprevir substitution on scored position     170l
Telaprevir substitution on scored position 170I

NS5A condons covered. 1-104
NS5A Region (w.r.t. D90208). - K6R, S17A, L31M, L34V, L37F,  G49A, Q54H, K68R, S101A
NS5A region (w.r.t. H77) I8V, E14T, S17A, K24Q, A25S, M28L, Q30R, L31M, I34V, V37F, R44K, G49A, R56T, H58P, E62Q, K68R, T71S, R78K, R81S, M83T, S85H, L101A
Resistance Analysis
Drug              Prediction                                           Scored mutations
Daclatasvir    reduced suspectibility                        31M
Elbasvir          resistant                                             31M
Ledipasvir      suspectible                                        31M
Ombitasvir    substitution on scored position         31M
Velpatasvir      supsectible                                       none

(Compl. Viekira+Exviera no Riba Nov2015. 1b,TT,F1, 1400000U start of treatm. After 2 weeks 120U. After a month below possib of detect. After 3 months UND.3EOT UND. 4wEOT RELAPSED,14Dec2016 VL 27000 IU.mL,Feb 2016 VL 24296 IU/mL,  May 2016 VL 106675 IU/mL .L31M in NS5A.Y93H not pres. No NS3 D168/A/F/H/N/Y)
2ndTreatmnt  geno 1b- Vosevi 12 weeks - SOT Sept 12 2018 to EOT Dec 5 2018. Pre-treatment - VL 1.4 mil, ALT 45, AST __, ALP 69, GGT 90, bilir 16. 2 weeklabs:VL 49, ALT 26, AST __, GGT 53. Bili 21, 4 weeklabs:VL <15, GGT42 other normal, 5weeklabs:ALT 17,AST 27, Bili 11.8,  ALP 68, GGT 36 ... VL 12,   6weeklabs ALT 19, AST 26, Bili 16,20, GGT35, VL<12

1stTreatm Compl. Viekira+Exviera no Riba Nov2015. 1b,TT,F1, 1400000U Relapsed 4 weeks EOT

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,544
  • Get tested, get treated, get cured, fight Hep c!
Re: I am waiting for Vosevi, a few questions
« Reply #1 on: May 20, 2018, 02:33:40 pm »
For your first question per the AASLD it looks like your odds of cure from clinical trial data is 100% I see no recommendation for ribavirin. See below

For your second question your reasearch is well beyond my capabilities so I leave that up to the molecular biologists. However, unless the odds of your initial treatment were 100% that would indicate it doesn’t work for everyone all the time. I relapsed with a 12 week treatment Sovaldi/ Olysio and later treated successfully with 24 weeks of Harvoni ribavirin. I know we will wonder why we fell on the wrong side of the data but we will likely never know. Several people here have had to be treated again and are now cured. I wish you the best and a successful treatment.


NS5A Inhibitor DAA-Experienced, Genotype 1 Patients With or Without Compensated Cirrhosis

Recommended Regimen
The placebo-controlled, phase 3 POLARIS-1 trial evaluated a 12-week course of the daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) in patients with a prior NS5A inhibitor-containing DAA regimen. The majority (61%) experienced a failure with a combination regimen of an NS5B inhibitor plus an NS5A inhibitor, such as sofosbuvir/ledipasvir (Bourliere, 2017). The overall SVR12 rate was 97% (146/150) in genotype 1-infected patients. SVR12 rates were 96% (97/101) for participants with genotype 1a infection and 100% (45/45) for those with genotype 1b infection. A single genotype 1-infected patient experienced relapse; this individual had subtype 1a infection and cirrhosis. Baseline RASs and the presence of cirrhosis were not significant predictors of virologic failure in genotype 1 infection. Serious adverse events were similar between the placebo and treatment arms; only 1 patient discontinued therapy due to an adverse event. Headache, diarrhea, and nausea were more common in those patients receiving sofosbuvir/velpatasvir/voxilaprevir compared to placebo.

Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.